Comparison of Consecutive Therapeutic Effects of Nanoemulsion and Emulsion Cyclosporin in Dry Eye Patients after Short-Term Treatment with Topical Fluorometholone

Table 3

Comparison of therapeutic effects at 12 weeks after treatment with topical FML and CsA between nanoemulsion and emulsion CsA groups.

	Group 1 (nanoemulsion CsA)			Group 2 (emulsion CsA)			value
	Baseline	12 weeks after treatment	value	Baseline	12 weeks after treatment	value
BCVA (logMAR)	0.08 ± 0.11	0.06 ± 0.11	0.390	0.12 ± 0.11	0.10 ± 0.11	0.407	0.264
IOP (mmHg)	9.4 ± 1.6	9.2 ± 1.4	0.888	9.8 ± 2.4	9.3 ± 2.7	0.723	0.639
SANDE score	73.9 ± 17.8	37.0 ± 19.7	<0.001	67.8 ± 24.1	41.3 ± 23.0	<0.001	0.803
TBUT (sec)	2.6 ± 1.1	5.3 ± 1.1	<0.001	3.1 ± 1.4	4.6 ± 1.4	<0.001	0.037
Schirmer (mm)	9.0 ± 7.6	11.1 ± 11.6	0.418	8.9 ± 7.2	6.7 ± 4.0	0.070	0.622
CSS (pts)	0.6 ± 1.1	0.1 ± 0.3	0.563	0.3 ± 0.7	0.5 ± 0.8	0.750	0.118
MGD grade	1.8 ± 0.4	0.9 ± 0.6	<0.001	1.9 ± 0.4	0.9 ± 0.3	<0.001	0.896
MG expression (pts)	2.6 ± 1.1	1.0 ± 0.5	<0.001	2.3 ± 0.7	1.2 ± 0.4	<0.001	0.274

Values are presented as the mean ± standard deviation. Intragroup analysis (the Wilcoxon signed-rank test); intergroup analysis (Mann–Whitney test). FML, 0.1% fluorometholone; CsA, 0.05% cyclosporine; BCVA: best corrected visual acuity; IOP, intraocular pressure; SANDE, symptom assessment in dry eye; TBUT, tear film breakup time; CSS, corneal staining score (NEI scale, 0–15); MGD, meibomian gland dysfunction; MG, meibomian gland. Statistically significant.